What's breaking now, across thousands of outlets.
MILAN — Lilly said Tuesday that its triple agonist, called retatrutide, helped patients with both obesity and type 2 diabetes to lose up to 18.8% of their weight after about a year and a half. Also ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
This is one outlet's version. Read the fullest account.
Though not yet approved by any regulatory agency, retatrutide could help improve blood sugar levels and reduce inflammation The ‘Godzilla’ of weight-loss drugs could help improve blood sugar levels, reduce inflammation and cut a person’s body weight by a quarter, according to the largest study of its kind.
A recent study found that both high-salt and severely low-salt diets impair memory in mice. While high salt triggers inflammation, extreme salt restriction starves the gut microbiome of metabolic byproducts needed for optimal brain function.
Merck agreed to pay SciBrunch up to $2.13 billion consisting of $400 million upfront and the remainder in payments tied to achieving milestones across multiple indications.
MILAN — Weight loss with Zealand and Roche’s amylin analog was regarded as disappointing when its Phase 2 obesity trial reported topline data in March.
‘The litigation did not originate with Mr. Ward, and its factual and legal foundation does not depend upon him,’ said the lawyer for dozens of Canadian soldiers and ex-soldiers named in the lawsuit
